World Courier network meets GxP requirements

By Staff reporter

- Last updated on GMT

Related tags: World courier, Quality assurance

World Courier has GxP compliant status for its whole distribution network, covering more than 140 offices in 50 countries, which it believes no other business in the sector has achieved on such a large scale.

The globalisation of pharmaceutical clinical trials, leading to many trial sites being located in developing countries, has placed new pressures on distribution networks and increased the need for proper handling of time- and temperature-sensitive transport.

To meet these evolving needs World Courier has formalised its GxP (good distribution / manufacturing / storage / clinical practice) compliance by taking several measures.

These include the development of a company-wide GxP policy, implementation of processes to enhance its ISO 9001 programme and the appointment of a global quality assurance (QA) team to ensure compliance on local, regional and corporate levels.

World Courier believes that by adopting an integrated, company wide approach it can ensure that all aspects of a client’s pharmaceutical storage and transport needs are safeguarded.

This spans temperature controlled transport of investigational drugs, biological samples and ancillary supplies to and from research sites, as well as the storage and distribution of materials from its 11 GMP-compliant drug depots.

Furthermore, World Courier aims to ensure the quality of its temperature controlled operations by employing experts who recommend the appropriate packaging from a range of thermal containment offerings.

The compliance of all these operations is monitored by the global QA team to ensure standards are maintained from start to finish. Wayne Heyland, president of the World Courier group, added that the company will continue to improve its processes.

He explained that “as the concept of 'quality' continues to evolve, our mission is to ensure that we evolve with it, and that we continue to lead – not follow – industry standards in this critical area​”.

Related news

Show more

Related products

show more

Import Risks & Clinical Supply Depots

Import Risks & Clinical Supply Depots

Catalent Pharma Solutions | 07-Nov-2018 | Case Study

A sponsor running a clinical trial in Israel arranged to ship their clinical trial product from Europe to a depot in Israel. With the protocol based in...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Discover Fermion’s new API unit 4 in Hanko

Discover Fermion’s new API unit 4 in Hanko

Recorded the 04-Sep-2018 | Webinar

Join this webinar to learn more about Fermion’s new manufacturing unit 4 at the Hanko site. This webinar will provide virtual tour to our new state of...

Related suppliers

Follow us


View more